Radiation Oncology
Expert insights on radiation treatment planning, techniques, toxicity management, and multimodal cancer care.
Recent Discussions
Do you typically recommend avoiding neupogen during radiation treatments?
It depends on the reason and expected benefit. If myelosuppression is holding up RT for cervical cancer patients, then I would not hesitate to give neupogen to avoid or minimize a treatment break. There would be more benefit to neupogen and continuing RT than a downside. Usually, I would try to give...
When would you consider initial induction chemotherapy (e.g. FOLFOX) followed by neoadjuvant chemoradiation, over neoadjuvant chemoradiation alone, in patients with locally advanced rectal cancer?
At MSKCC, we now routinely recommend induction chemotherapy (8 cycles of FOLFOX) to any rectal cancer patient who requires preoperative chemoRT. Initially, we adopted this approach for patients with particularly bulky or node-positive disease (as per @Dr. First Last's answer above) but now do it for...
For marginal recurrences of skin cancers after prior hypofractionated radiation therapy (i.e., 30 Gy/5 fx, 55 Gy/20 fx) where there is concern for overlapping fields, could reirradiation with a hypofractionated course be considered?
For a marginal recurrence of a cutaneous malignancy after definitive hypofractionated RT, I would not necessarily offer reirradiation. I would have my plastic/dermatologic surgeon see the patient for consideration of surgical salvage, which may likely require an advanced reconstruction. If the patie...
Do you boost a breast cavity for a high Ki-67 index in the absence of other risk factors?
Ki-67 has some level of subjectivity with inter-individual variation. If genomic testing, like Oncotype or Mammaprint, has been done, I would favor using that to decide whether the patient is low risk or not over k1-67 alone.
Would you offer PMRT to a patient with potential metastatic disease?
If an additional ER scan is planned, I will wait to see the results. If there are unequivocal mets, I would not offer PMRT; otherwise, I would offer PMRT. If PMRT is offered, I will start endocrine therapy, but add the CDK4/6 inhibitor after RT is done.
How do you counsel patients about prognosis with FIGO 2018 IIIC cervix cancer managed in the new era of chemoradiation plus immunotherapy?
The prognosis is still a function of nodal location, number of nodes, local T stage, histology, and response to the EBRT portion of treatment. The local control is closer to 90% with a predominant pattern of failure being distant (around 20-25%). Also based on A-18, 3 years PFS is around 70% and OS ...
How would you manage new symptomatic brain metastases (10-15) in a young woman with HER2+ metastatic breast cancer?
A lot of nuance to answering this on a per-patient basis.First question, how symptomatic? (As in, are there bulky mets that we should be considering surgical management upfront plus this also guides my discussion about whole brain vs systemic)If not acutely symptomatic and requiring a crani/resectio...
How would you treat pelvic node recurrence after prior RP and adjuvant XRT prostate bed only?
RT to pelvic nodes to aortic bifurcation, boost positive nodes, plus ADT.
In what situations would you routinely offer 25 Gy/5 fx for glioblastoma?
We use this regimen in two situations, based on clinical need. Ultra short course in very poor performers unwilling for more elaborate treatment and needing very short term palliation. Recurrent GBM's, not resectable but reasonable targets for SRS, but too large for single session 15-17Gy in one se...
What is your approach for LINAC based radiosurgery when dealing with benign perioptic lesions very close to the optics apparatus?
It all starts with the consideration of what I consider an effective dose of SRS or SRT (hypo-fractionated SRS). The minimum effective dose to achieve local control of a metastatic lesion is usually 18 Gy for single fraction, 27 Gy for 3 fractions, and 30 Gy in 5 fractions.I then consider the histol...